Related Experiment Video
Updated: Jun 3, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
[Liver toxicity of micafungin. Is this drug safe?]
Maricela Valerio1, Patricia Muñoz, Emilio Bouza
1Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, España.
Abstract:
Micafungin was commercialized in Japan in 2002 and has been used in more than 750,000 patients. As a member of the candin family, the drug's clinical and analytical tolerability is very good, both in adults and in children, including neonates. In this latter population, micafungin is the most frequently used candin. The most common adverse effects are nausea and elevated transaminase levels. Preclinical studies showed the development of benign liver tumors in rats treated with extremely high doses of the drug for prolonged periods. These data were not reproduced in other species and no cases have been reported in humans.
Related Concept Videos
Antifungal Agents
Drug toxicity: Drug–Drug Interaction
Fungal Phylum Microsporidia
Drug Toxicity: Overview
Drug Toxicity: Risk factors
Drug Toxicity: Dose-Dependent Reactions

